

## MYELOFIBROSIS: face the future by challenging the past

## 1st day Thursday May 20, 2021

15:00 Welcome and introduction G. Martinelli

15:15 FIRST SESSION: BIOLOGY/PATHOLOGY

Chair G. Martinelli P. Tosi

15:15 Biological drivers of progressive disease

- Genetics of inflammatory response in MPNs

M.T. Bochicchio

- RNA polymorphisms to stratify the risk of progression

E. Masselli

**Discussion** 

15:55 Immune escape mechanisms in MF

M.O. Holmstrom

Discussion

**16:20 Lecture** 

Murine models of MF: inflammasome and beyond, novel targets from Gata1 low mice A.R. Migliaccio

16:50 SECOND SESSION: NOVEL PATHWAYS, NOVEL TARGETS

Chair G. Musuraca F. Lanza

16:50 Megakaryocyte-biased hematopoiesis in myelofibrosis

B. Psaila

17:15 Driver mutations as targets for immune cell therapies

M.O. Holmstrom

**Discussion** 

## 2nd day Thursday May 21, 2021

15:00 Welcome and introduction G. Rosti

15:10 THIRD SESSION: JAK INHIBITORS

Chair G. Rosti

15:10 Clinical experience and state of the art in JAK inhibition

M. Bonifacio

15:30 From JAK2 to novel targets: time for a combination therapy?

S. Galimberti

Discussion

16.00 FOURTH SESSION: MYELOFIBROSIS AND AUTOIMMUNITY

Chairs V. Di Battista M. Poggiaspalla

16:00 Autoimmune myelofibrosis, autoimmune disease in overlap MPNs

C. Fava

16:20 Targeting inflammasomes in rheumatic disease

F. Carubbi

**Discussion** 

16.50 FIFTH SESSION: STOP COUNTING PLATELETS - TOWARDS

Chairs G. Simonetti G. Giordano

16:50 Circulating microvescicles and their potential clinical impact

L. Catani

17:10 Aspirin dependent expression of platelet fibrinogen receptors

A. Lucchesi

17:30 Global coagulation assays and their usefulness in MPNs

M. Napolitano

**Discussion** 

18.00 Closing Remarks C. Fava A. Lucchesi